Summary
The AI statements do not align with the provided FDA label excerpts for VANDAZOLE (metronidazole 0.75% vaginal gel). Major inaccuracies include incorrect active ingredient and incorrect indication/route and failure to include key labeled cautions/contraindications/interactions for VANDAZOLE.
Category Scores
Accurate Statements
People with a known allergy to terbinafine or any ingredient in the gel should not use it.
Unsupported relative to the provided VANDAZOLE (metronidazole gel) label excerpts; label contraindication is hypersensitivity to metronidazole, other nitroimidazole derivatives, or parabens (4.1).
Vandazole gel is a topical (skin) treatment.
Contradicted by label route: administered intravaginally and not for dermal/oral/ophthalmic use (2 DOSAGE AND ADMINISTRATION).
Unsupported Statements
Vandazole gel is an antifungal medicine for treating fungal skin infections.
Provided label excerpt indicates VANDAZOLE is for bacterial vaginosis (1 INDICATIONS AND USAGE), not antifungal treatment of fungal skin infections.
Vandazole gel is used for conditions such as ringworm and other superficial fungal infections of the skin.
No support in provided label excerpt; VANDAZOLE indicated for bacterial vaginosis in post-menarchal females (1).
Vandazole gel contains the antifungal drug terbinafine.
Label excerpt identifies VANDAZOLE as metronidazole gel, USP, 0.75% (drug identity implied by provided labeling context); contraindications/interactions are for metronidazole/nitroimidazoles, not terbinafine.
Vandazole gel is applied as a thin layer to the affected skin area and gently rubbed in.
Label excerpt specifies intravaginal administration (2) and does not support dermal/rubbing instructions.
Vandazole gel instructions include washing hands after use unless the hands are the treated area.
Not supported by the provided label excerpts (no such counseling text included).
Vandazole gel should be used regularly for the course advised by a clinician or the product label.
While general phrasing resembles adherence, the provided label excerpt specifies a specific regimen (one applicator full intravaginally once daily for 5 days at bedtime). This statement is not directly supported as written.
Visible improvement with topical antifungals often takes a few days.
Label excerpt provided is for bacterial vaginosis; no such statement about “topical antifungals” or timeline is supported.
Complete clearing with topical antifungals usually requires finishing the full treatment period to reduce the chance of relapse.
Not supported in provided excerpts; applies to antifungals rather than VANDAZOLE’s labeled indication/regimen.
Topical antifungals can cause local skin reactions such as mild irritation, redness, itching, or a burning sensation where applied.
No support in provided excerpts for these specific “skin reaction” examples; provided label adverse reactions are for VANDAZOLE in bacterial vaginosis and include pruritus and other vaginal/clinical-trial findings.
Vandazole gel should be used only after asking a clinician before using on broken skin, near the eyes/mouth, or in children if the label requires medical guidance.
Label excerpt explicitly states “Not for ophthalmic, dermal, or oral use” (2). It does not support the conditional phrasing, and children-specific guidance is not provided in the user text.
Multiple antifungal or irritating products should be avoided on the same area unless a clinician advises it because it can increase irritation.
Not supported by provided label excerpts.
Oral antifungal tablets are used for some deeper or widespread infections and require different dosing and medical supervision.
Not supported by provided label excerpts; VANDAZOLE is a metronidazole vaginal gel with specified intravaginal regimen (2) and label does not discuss antifungal oral tablets in the provided text.
Contradictions
High
AI Statement
Vandazole gel is an antifungal medicine for treating fungal skin infections.
Label Reference
1 INDICATIONS AND USAGE: VANDAZOLE is indicated in the treatment of bacterial vaginosis in post-menarchal females.
High
AI Statement
Vandazole gel contains the antifungal drug terbinafine.
Label Reference
Provided label excerpts correspond to VANDAZOLE (metronidazole gel, USP, 0.75%), with contraindications for metronidazole/nitroimidazole derivatives (4.1) and disulfiram/alcohol cautions (4.2, 4.3/7.2).
High
AI Statement
Vandazole gel is applied as a thin layer to the affected skin area and gently rubbed in.
Label Reference
2 DOSAGE AND ADMINISTRATION: administered intravaginally; “Not for ophthalmic, dermal, or oral use.”
High
AI Statement
Vandazole gel is a topical (skin) treatment.
Label Reference
2 DOSAGE AND ADMINISTRATION: administered intravaginally; not for dermal use.
Medium
AI Statement
Vandazole gel should be used only after asking a clinician before using on broken skin, near the eyes/mouth, or in children if the label requires medical guidance.
Label Reference
2 DOSAGE AND ADMINISTRATION: “Not for ophthalmic, dermal, or oral use.”
Important Omissions
Correct indication: bacterial vaginosis in post-menarchal females.
Importance:
High
Correct dosage and regimen: one applicator full (~5 g; ~37.5 mg metronidazole) intravaginally once daily for 5 days, administered at bedtime.
Importance:
High
Key contraindications: hypersensitivity to metronidazole/other nitroimidazoles/parabens; disulfiram use within 2 weeks.
Importance:
High
Alcohol and ethanol/propylene glycol restriction during and for at least 3 days after therapy.
Importance:
High
Drug interaction monitoring considerations: coumarin/oral anticoagulants (consider monitoring INR/prothrombin time) and lithium (consider monitoring lithium levels).
Importance:
Moderate
Warnings/precautions: CNS effects and guidance to discontinue promptly with abnormal neurologic signs; interference with laboratory tests (consider postponing serum chemistry determinations until completed).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple high-severity contradictions (incorrect drug identity/active ingredient, incorrect indication, and incorrect route of administration/skin use) are present, which could lead to inappropriate treatment and unsafe administration relative to the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Statements are largely inconsistent with the supplied VANDAZOLE (metronidazole vaginal gel, 0.75%) prescribing information, including incorrect active ingredient, indication, and administration route.
Suggested Improvement
Replace all antifungal/terbinafine/skin infection/ringworm statements with VANDAZOLE-specific label content: indication for bacterial vaginosis in post-menarchal females and intravaginal dosing once daily for 5 days at bedtime, and include labeled contraindications (metronidazole/nitroimidazole/parabens hypersensitivity; disulfiram within 2 weeks), alcohol restriction, and key warnings/precautions (CNS effects, laboratory test interference).